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Abstract: For a long time, sample preparation was unrecognized as a critical issue in the 
analytical methodology, thus limiting the performance that could be achieved. However, 
the improvement of microextraction techniques, particularly microextraction by packed 
sorbent (MEPS) and solid-phase microextraction (SPME), completely modified this 
scenario by introducing unprecedented control over this process. Urine is a biological fluid 
that is very interesting for metabolomics studies, allowing human health and disease 
characterization in a minimally invasive form. In this manuscript, we will critically review 
the most relevant and promising works in this field, highlighting how the metabolomic 
profiling of urine can be an extremely valuable tool for the early diagnosis of highly 
prevalent diseases, such as cardiovascular, oncologic and neurodegenerative ones. 
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1. Introduction 
The development of an analytical method includes several steps, such as sampling and extraction, 
analysis and, finally, the mathematical processing. All of them greatly influence the analytical performance 
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that can be achieved in terms of reliability, accuracy, precision and sensitivity, as well as the time and 
cost of analysis. In several cases, over 80% of analysis time is spent on sampling and sample 
preparation steps, including homogenization, extraction, concentration and clean-up. This is necessary 
for several matrices, such as the biological ones, once the analytical instruments cannot handle the 
sample complexity directly. Therefore, sample preparation has been recognized as the main bottleneck 
of the analytical process, particularly for the analysis of trace components [1,2]. 
In this sense, an ideal sample preparation should present the following features: (i) minimal sample 
loss and a maximum recovery of the target analyte; (ii) elimination of coexisting components with a 
high yield; (iii) a simple, fast and inexpensive method; (iv) compatibility with the following analytical 
instruments; and (v) in conformity with green chemistry demands [3–7]. Microextraction techniques 
(METs), which use a minimal extractant amount (sorbent or liquid phase) offer these benefits and are 
becoming widely used in different fields, such as the biomedical, food, forensic and environmental 
ones, just to name the most frequently described applications (reviewed in [8–13]). 
Figure 1. Classification of microextraction techniques (METs). 
 
Abbreviations: FNME, fiber-packed needle microextraction; MEPS, microextraction by packed sorbent; 
SBSE, stir-bar sorptive extraction; SPDE, solid phase dynamic extraction; SPME, solid-phase microextraction; 
TFME, thin film microextraction. 
The recent advances in this field have converged on the miniaturization and integration of sample 
preparation online with analytical instrumentation, in order to reduce laboratory workload and to 
increase analytical performance [14]. From this perspective, METs have emerged in the last few years as 
powerful sample preparation approaches suitable for easily automating with liquid and gas 
chromatographic systems applied in a diversity of bioanalytical areas. Nowadays, there are several 
MET formats available that can be grouped in liquid-phase and solid-phase METs (Figure 1). In the 
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first group, we have the single-drop and the membrane-assisted microextractions variants. The second 
group, the solid-phase METs, can be organized according to the diffusion process in stirring and flow 
through versions. Nevertheless, solid-phase microextraction (SPME) in its different formats and 
microextraction by packed sorbent (MEPS) are certainly two of the most successful METs currently 
used with an increasing range of applications. Moreover, the aim of this review is to discuss the main 
advantages of using urine as a biological matrix suitable for diagnostic purposes combined with high 
throughput analytical techniques.  
2. Extraction Techniques 
2.1. Solid-Phase Microextraction (SPME) 
SPME was introduced by Arthur and Pawliszyn in the early 1990s [15], and it is based on the 
partitioning of target analytes between the sample and the stationary phase, which is typically coated in 
the surface of a fused silica fiber (1–2 cm). The analytes are then thermally desorbed in a gas 
chromatography (GC) injector port or removed by solvents for high performance liquid chromatography 
(HPLC) or electrophoresis applications and subsequently analyzed. This combination allows for an 
excellent analytical performance for the quantification of different chemical families [16–18]. 
The main SPME advantages are the simplicity of operation, its solventless nature, analyte/matrix 
separation and pre-concentration, the availability of different commercial fibers, as well as the 
developments toward the automation of the whole process that have made SPME a routinely used tool 
in food, environmental, clinical, pharmaceutical and bioanalysis applications [19–21]. Its use in 
analytical laboratories is, therefore, expected to continue to grow in the future [22]. The generally 
accepted drawbacks are a relatively poor reproducibility, lot-to-lot variations, the lack of selectivity, 
sensibility against organic solvents, the latter frequently preventing liquid sampling, and their cost. 
Nevertheless, possibly the most important disadvantage is the limited range of stationary phases 
available, only roughly covering the scale of polarity (see Figure 2) [23,24]. Fiber coating procedures, 
which included sol-gel technology, electrochemical methods and physical deposition, provide a wide 
range of homemade coatings, which can sort out some of the drawbacks associated with the 
commercial fibers [24,25]. 
2.1.1. SPME Technical Aspects and Analytical Performance 
2.1.1.1. Extraction Mode 
For the SPME extraction, fused silica coated fiber can be introduced into the sample in three 
different ways: (i) direct extraction; (ii) headspace (HS-SPME); and (iii) extraction with membrane 
protection. Obviously, there are many factors affecting both of these sampling procedures, and some of 
these will be discussed in the current manuscript [22,26,27]. The extraction efficiency of each mode 
depends on the analytes properties and the sample matrix (reviewed in [22]). 
(i) Direct extraction (DI-SPME) 
The coated fiber is directly immersed in the aqueous samples, and the analytes are transported 
directly from the sample matrix into the extracting phase. The sample agitation is often carried out 
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with a small stirring bar to decrease the time necessary for equilibration time and to improve the 
analyte transportation from the sample bulk to the fiber vicinity [28,29]. 
(ii) Headspace (HS-SPME) 
In headspace mode, the analytes are extracted from the gas phase above a gaseous, aqueous or solid 
sample. The primary reason for this modification is to protect the fiber from adverse effects caused by 
non-volatile, high molecular-weight substances present in the sample matrix (e.g., proteins). The headspace 
mode also allows for matrix modifications (including pH adjustment) without affecting the fiber. In a 
system consisting of a liquid sample and its headspace, the amount of an analyte extracted by the fiber 
coating does not depend on the location of the fiber (in the liquid or gas phase) [28]. The analyte 
amount sorbed on the fiber, and the resulting sensitivity, are determined both by sorption kinetics and 
the distribution coefficient of the compound between the coating fiber, the headspace and the sample 
(reviewed in [30]). 
(iii) Extraction with membrane protection 
A selective membrane separated the sample from the fiber, which lets the analytes through, while 
blocking the interferences. The main purpose for the use of the membrane barrier is to protect the fiber 
against adverse effects caused by high molecular-weight compounds when very complex samples  
are analyzed [28]. 
2.1.1.2. Coating Fibers 
Several types of stationary phases, of different thicknesses and polarities, are commercially 
available (Supelco, Gland, Switzerland ), showing great selectivity for different analytes, namely three 
poly(dimethylsiloxane) (PDMS) films of different thicknesses (seven, 30 and 100 µm), 85 µm 
polyacrylate (PA), the 60 and 65 µm polydimethylsiloxane/divinylbenzene (PDMS/DVB) mixed 
phases, 75 µm carboxen/polydimethylsiloxane (CAR/PDMS), 60 µm polyethylene glycol (PEG), 50 µm 
carbowax/templated resin (CW/TPR) and 50/30 µm divinylbenzene/carboxen/polydimethylsiloxane 
(DVB/CAR/PDMS). Stationary phases are immobilized by non-bonding, bonding, partial crosslinking 
or high crosslinking (Figure 2). Non-bonded phases are stable with some water-miscible organic 
solvents, although some swelling may occur when used with non-polar solvents. Bonded phases are 
stable with all organic solvents, except for some non-polar solvents. Finally, partially crosslinked phases 
are stable in most water-miscible organic solvents and some polar solvents, while highly crosslinked 
phases are similar to the latter, except that some bonding to the core may occur (reviewed in [22]). 
Regarding fiber polarity, polar fibers are effective for extracting polar analytes, and nonpolar fibers 
are effective for extracting the nonpolar analytes from different matrices. Fibers with different polarities 
provide high extraction selectivities and reduce the possibility of extracting interferences. For example, 
PDMS/DVB, PDMS/CAR and PEG fiber coatings are more polar than those containing PA, and for 
this reason, they are more often used to extract highly polar compounds, like alcohols and carboxylic 
acids; on the other hand, CAR is responsible for the CAR/PDMS coating’s greater specific surface 
area, and this results in a very efficient extraction of volatile organic compound (VOC) analytes [25]. 
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Figure 2. Properties of commercially available SPME fibers (adapted from [31]). CW/TPR, 
carbowax/templated resin; PEG, polyethylene glycol; PDMS, poly(dimethylsiloxane); 
DVB, divinylbenzene; PA, polyacrylate; CAR, carboxen. 
 
2.1.1.3. Extraction Time and Temperature 
Extraction time and temperature are two of the most important parameters affecting the SPME 
extraction efficiency. The extraction time is dependent on the partition coefficient of the analyte between 
the fiber coating and the sample matrix and also on the sample stirring, this being generally shorter for 
extractions from the headspace. SPME has a maximum sensitivity at the equilibrium point, defined as 
the time after which the level of analyte extracted remains constant, corresponding to the limit of 
experimental error to the amount extracted after infinite time. At equilibrium, small extraction time 
variations do not affect the level of analyte extracted by the fiber. Moreover, full equilibration is  
not necessary for accurate and precise analysis by SPME, due to the linear relationship between the 
amount of analyte adsorbed by the SPME fiber and its initial concentration in the sample matrix in 
non-equilibrium conditions (reviewed in [22,30]). 
SPME extraction is an exothermic equilibration process and, therefore, the increase in the extraction 
temperature causes an increase in the extraction rate, and simultaneously, the distribution constant 
decreases [28]. On the other hand, the headspace-analyte partition coefficient increases with higher 
sampling temperature, resulting in a higher analyte concentration in the headspace and a consequent 
shorter extraction time [22]. In the case of natural product extraction, less aggressive conditions should 
be applied, such as moderate temperature and protection from light and oxygen, to prevent the 
degradation of some thermosensitive compounds. 
2.1.1.4. Ionic Strength 
The salt addition can influence the extraction efficiency by changing the properties of the boundary 
phase and decreasing the solubility of hydrophilic compounds in the aqueous phase (salting-out  
effect) [32]. However, the salt addition is preferred for HS-SPME, because fiber coatings are prone to 
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damage during agitation by direct extraction (DI)-SPME. For this purpose, sodium chloride, sodium 
hydrogen carbonate, potassium carbonate and ammonium sulfate are generally used [22]. 
2.2. Microextraction by Packed Sorbent (MEPS) 
MEPS was introduced by Abdel-Rehim in 2004 [11]. It is a miniaturization of the conventional 
solid-phase extraction (SPE)-packed bed devices from milliliter bed volumes to microliter volumes, 
which can be connected online to gas chromatography (GC) and/or liquid chromatography (LC) without 
any further modifications [33]. This technique has been successfully used to extract a wide range of 
analytes in different biological matrices, such as urine, plasma, saliva and blood [11,34,35]. 
In MEPS, approximately 1–2 mg of the sorbent is packed inside a syringe (100–250 µL) as a plug 
or between the barrel and the needle as a cartridge. Sample extraction takes place in this packed bed, 
which can be coated to provide selective and suitable sampling conditions. The MEPS approach to 
sample preparation is suitable for reversed phases (extraction of hydrophobic analytes or polar organic 
analytes from aqueous matrices), normal phases (extraction of polar analytes from non-polar organic 
solvents) and mixed mode and ion exchange chemistries (extraction of charged analytes from aqueous 
or non-polar organic samples) [9,34,35]. There are several available MEPS sorbent materials  
(Figure 3), including reversed phase (C18, C8 and C2), normal phase (silica), restricted access material 
(RAM), HILIC (hydrophilic interaction liquid chromatography), carbon, polystyrene-divinylbenzene 
copolymer (PS-DVB), molecular imprinted polymers (MIPs), strong cation exchange (SCX) and 
mixed mode (C8/SCX) chemistries (reviewed in [9,35]). 
Figure 3. Simplified flowchart for MEPS sorbents selection. The parameters used were the 
matrix properties (aqueous or organic), the polarity and solubility of the target analytes 
(soluble in water or organic solvents) and the extraction mode (reverse-phase (RP),  
ion-exchange (IE) or normal-phase (NP)). Adapted from [9]. APS, AminoPropyl Siloxane; 
AX, Anion eXchange; CX, Cation eXchange; HDVB, Highly cross-linked polystyrene 
DiVinylBenzene; PEP, Polar Enhanced Polymer; SAX, Strong Anion eXchange; SCX, 
Strong Cation eXchange; SDVB, polyStyrene DiVinylBenzene. 
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This extraction method differs from commercial solid-phase extraction (SPE) in that the packing is 
integrated directly into the syringe and not into a separate column. Furthermore, the packed sorbent 
can be used more than 100 times, even when using plasma or urine samples, but a conventional SPE 
column is used only once. Moreover, MEPS can handle low sample volumes (10 µL) to large volumes 
(1,000 µL). The analytes are then eluted with small volumes of an organic solvent, such as methanol or 
other mobile phases, allowing for a very significant concentration of the target when large sample 
volumes are used. The combination of MEPS and chromatographic techniques, such as GC-MS, HPLC 
and LC-MS/MS, is an excellent tool for the screening and determination of biomarkers in biological 
samples. This approach for sample preparation is therefore very promising for many reasons, namely 
that: (1) it is fast and easy to use; (2) it can be fully automated for online procedure; (3) it reduces the 
solvent and sample volume, as well as the waste produces; and (4) the cost of analysis is minimal when 
compared to conventional SPE. Overall, it is one of the most user- and environmental-friendly METs 
available for sample extraction. 
MEPS is a very simple and straightforward MET, but it nevertheless involves a wide range of 
optimization steps that allow for a fine tuning of the extraction efficiency.  
2.2.1. MEPS Influencing Parameters 
2.2.1.1. Sampling 
Biological fluids, like urine, blood and plasma, are complex samples and should be processed 
accordingly to optimize the extraction of the target analytes by favoring a better interaction between 
sample analytes and the sorbent [35]. This involves the dilution of the sample (to reduce the sample 
viscosity), pH adjustment (to reduce the ionization of weak acids and bases for reversed-phase 
extraction), deproteination (with previous protein precipitation, for instance) and sample loading speed 
adjustment (an option in semi-automatic and automatic MEPS (reviewed in [9,35]). 
2.2.1.2. Number of Extraction Cycles (Draw-Eject) 
In MEPS, the sample can be drawn through the needle into the syringe, once or several times  
(draw-eject), leading to a higher recovery level that should be optimized for each application. The 
multiple extraction cycles can be made from the same aliquot (draw-eject in the same vial) or by 
drawing up from an aliquot and discarding as waste (extract-discard) [35]. 
2.2.1.3. Sorbent Type 
This is probably one of the most important parameter to get high extraction recoveries in MEPS. 
There are nowadays many sorbent types available, from silica to polymeric and mixed-mode phases, 
functionalized or not, and even a porous graphitic carbon sorbent. In a simplified way, silica C2–C18 
phases are more suitable for lipophilic analytes (non-polar) and polymeric phases, such as  
polystyrene-divinylbenzene or mixed-mode phases (anion-cation exchange mode), are more indicated 
for polar analytes such as acidic and basic compounds (reviewed in [9,35]). Nevertheless, in a 
significantly number of reports, custom sorbents, mainly molecular imprintings (MIPs) of the target 
analytes, have been successfully developed. Using this MIMEPS approach (MEPS using custom MIPs 
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sorbents [9]), a higher analytical performance can be obtained in the following analytical procedures, 
and therefore, this format will certainly become more popular as they start to be commercially available. 
2.2.1.4. Washing Solution 
In this step, unwanted and weakly retained interferents can be washed away. The solvent concentration 
and the pH are important factors to decrease the leaking of the target analytes under the washing process. It 
was shown, for instance, that the analyte leakage increased as the solvent percentage in the washing 
solution increases [35]. 
2.2.1.5. Elution Solution 
The elution solution should be an organic solvent, like methanol, isopropanol or acetonitrile, pure or 
mixed with acid or base solutions (0.1%–3%), and should be able to displace all analytes from the 
sorbent in a small volume (20–50 µL). Moreover, the solvent and the pH of the elution solution have a 
large influence on the recovery efficiency. The analyte elution increases as the solvent percentage and 
elution volume increase [35]. However, the best elution solvent should elute the maximum amount of 
analyte using the smallest volume possible, therefore increasing the target analyte concentration. 
Overall, as represented in Figure 4, MEPS and SPME present several optimization opportunities 
that should be carefully explored in order to improve the extraction of the target analytes. 
Figure 4. Most influent parameters in MEPS and SPME optimization. 
 
Miniaturized analytical techniques had gained attention due to their many special features over 
conventional approaches. Among many advantages, the usage of little or no solvent, the low volumes 
of the sample required, the greater sensitivity in the sample preparation than for the exhaustive 
extraction procedures, the increasing of the sensitivity of analysis and a user-friendly system should be 
pointed out (Table 1). 
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Table 1. A comparison of some characteristics of target sample preparation techniques 
with solid phase extraction procedures. Reviewed in [11,36]. 
Factor MEPS SPE SPME 
Sorbent amount 0.5–4 mg 50–2,000 mg 150 mm Thickness 
Sample preparation time 1–2 min 10–15 min 10–40 min 
BIN (Barrel insert  
and needle) use 
40 to 100 
extractions 
Single use 50–100 extractions 
Sample throughput low high high 
Recovery good good low 
Sensitivity good good low 
Carryover low high high 
Cost low high high 
3. Metabolic Profiling of Urine: Recent Trends 
Metabolomics can be defined as a method to assess the metabolite complexity of a given sample, 
and it involves the quantification of all metabolites in that sample. This approach allows for the 
evaluation of an extensive range of endogenous and exogenous metabolites that have an impact on the 
investigation of the physiologic status, the identification of biomarkers, the biochemical pathways that 
have been altered and the diagnosis of various diseases. The small-molecule metabolites are important 
in biologic systems and are potential candidates to understand disease phenotypes. These metabolites 
constitutes a wide group of low molecular weight compounds that include lipids, peptides, amino 
acids, nucleic acids, organic acids, carbohydrates, thiols, vitamins, etc., and their characterization 
allows for obtaining unique “fingerprints” [37,38]. This provides an outstanding tool to assist disease 
diagnosis and prognosis and to identify new therapeutic targets and treatments. Additionally, 
metabolomics is also an important tool for many other applications, such as toxicology, environmental 
stress, nutrition, effects of genetic manipulation, identification of natural products, monitoring of donor 
organ viability and the establishment of genomic-metabolomic correlations. Recently, metabolomics 
has been focused on the identification of biomarkers for several diseases, namely cardiovascular (CVDs), 
oncologic (ODs) and neurodegenerative diseases (NDDs) [37–39]. 
In the course of history, urine has been a significant marker of health and illness. Hippocrates  
(460–355 BC) began using urine as a tool to diagnose disease and hypothesized that urine was a filtrate 
of the humors. Galen (AD 129–200) defined urine as a filtrate from blood and began to use it to 
characterize diseases that are recognized as diabetes mellitus and renal failure. Nowadays, urine 
analysis (urinalysis) has been well established as a diagnostic tool [39]. 
The use of urine as an analytical tool presents more advantages over other biological samples, such 
as blood, serum, plasma or tissue, since it can be obtained in large amounts by non-invasive sampling, 
requires no patient preparation and can be performed as often as needed [40,41]. Furthermore,  
in comparison with other biological fluids (Figure 5), urine presents lower protein content and sample 
complexity (mainly constituted by water, ions, creatinine and urea), including less intermolecular 
interaction, and thus, less sample pre-treatment is necessary [37–39,42]. As end products of normal 
and pathologic cellular processes, the metabolites present in urine are closely linked to phenotypes. 
Due to this, many efforts have been made over the last 10 years to study urinary metabolomics and to 
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use it as a diagnostic tool [43]. Urinalysis became an excellent tool to obtain information about metabolite 
concentrations and pathways, errors in the normal metabolism, drug interactions and therapeutic drug 
monitoring (TDM), exposure to exogenous chemicals, drug abuse, particularly the illicit ones, doping 
control, nutrition and dietary intake, including food contaminants (reviewed in Zhang et al. [38]). For 
example, after soya consumption, daidzein, genistein and total isoflavonoids were found to be higher 
in urine samples [44], but in turn, the same urinary levels of genistein, total isoflavones and 
metabolites were reduced during antibiotic use [39]. For the development of specific biomarkers, it is 
important to decipher the complex molecular networks that characterize disease states [38]. For 
instance, the diagnostics methods that are usually employed are incapable of predicting jaundice 
syndrome (JS) in patients with liver disease. However, the results of one metabolomic study clearly 
revealed the potential of urine metabolomics in the diagnosis of this pathophysiology [45]. Urinary 
metabolites may be also very important for the non-invasive screening of pre-diabetic subtypes, which 
could lead to an early and personalized intervention for this disease [38]. Aiming for the 
characterization of metabolic indicators for type 2 diabetes mellitus (T2DM), Temmerman et al. [46] 
used LC-MS, GC-MS and NMR data from urinalysis to report a cross-platform for the urinary 
metabolome of T2DM. This allowed them to show significant up and down variations in the levels of 
several metabolites under hyperglycemia in T2DM. 
Urinalysis has been also used to search for metabolite signatures that could be associated with 
cancer. In this way, several studies showed that low molecular weight urinary volatile organic 
compounds (VOCs) could be used as biomarkers for lung cancer, urine metabolomics having an 
excellent sensitivity (93%) and specificity (94%). Some metabolites of interest included  
β-hydroxyisovalerate, hippurate, α-hydroxyisobutyrate and creatinine [38,47]. 
Regarding the high prevalency breast and ovarian cancers, some qualitative and quantitative 
metabolomic methodologies have shown promising metabolic changes. Slupsky et al. [48], for 
instance, using NMR urinalysis, reported that intermediates of the tricarboxylic acid cycle and 
metabolites related with energy metabolism, amino acids and gut microbial metabolism were 
perturbed. This data is in agreement with the report from Serkova et al. [49], showing that several 
metabolic biomarkers related to glycolysis, mitochondrial citric acid cycle, choline and fatty acid 
metabolism are important in carcinogenesis and are responsive to anticancer treatment. Regarding this, 
Cho et al. [50] performed a targeted metabolite profiling of 14 urinary nucleosides in pre- and  
post-operative breast cancer female patients. The results showed levels of modified nucleosides  
(5-hydroxymethyl-2′-deoxyuridine, 8-hydroxy-2' -deoxyguanosine (8-OHdG), 1-methyladenosine and 
N(2),N(2)-dimethylguanosine) as being significantly higher in pre-operative patients than in both 
normal controls and post-operative patients. In the same direction, Loft et al. [51] observed a positive 
association between the urinary level of the oxidative stress biomarker, 8-OHdG, and the risk of 
especially estrogen receptor-positive breast cancers. Finally, Nam et al. [52] reported that urinary 
levels of homovanillate, 4-hydroxyphenylacetate, 5-hydroxyindoleacetate and urea were also altered in 
breast cancer patients. 
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Figure 5. Comparison of the main aspects of the most common biological matrices. 
 
Abbreviations: CSF, cerebrospinal fluid. 
Acute kidney injury (AKI) is another extensively studied clinical perturbation, due to its high 
incidence, mortality and morbidity. This justifies the search for suitable biomarkers, as the existing 
one, the monitoring of serum creatinine, presents poor analytical performance, being unspecific for 
AKI and highly influenced by other variables, such as gender, age, muscle mass and metabolism, drugs 
and hydration. Furthermore serum creatinine is not targeted for the early detection of disease [37]. 
Therefore, urine became a preferred matrix to search for new biomarkers for renal injury. Regarding 
this, Kim et al. [53] studied the potential of urine metabolomics to find important metabolites in  
kidney cancer and reported that some compounds related with amino acid and energy metabolism,  
such as quinolate, 4-hydroxybenzoate and gentisate, were differentially expressed [38]. 
Taylor et al. [54] performed a GC-MS metabolomics urinalysis of juvenile cystic mice to study 
kidney disease and found several changes in the purine and galactose metabolism pathways. In this 
report, allantoic acid and adenosine were identified as putative biomarkers of kidney disease that can 
now be studied in human urine. McClay et al. [55] performed NMR urine metabolomics to investigate 
the metabolic profiles of patients with chronic obstructive pulmonary disease (COPD) and showed that 
this approach was extremely useful for its diagnosis [37,55]. Michell et al. [56] studied Parkinson’s 
disease (PD) using a GC-TOFMS (Time-of-flight mass spectrometry) urine and serum profiling and 
observed changes in the urinary metabolite profiles that could be used for its diagnosis. However, the 
signatures obtained are still highly multivariated, and further experiments are necessary to assign 
specific urinary biomarkers for PD. Asthma was also studied using an untargeted metabolic approach 
for urine samples, and the profiles obtained revealed a potential to characterize the disease and to 
determine metabolites that may have a role in the principal pathogenic mechanisms [57–59]. The 
metabolites detected by Jung et al. [60] in patients that suffered from strokes showed that the urinary 
metabolomic approach may also be useful for the diagnosis of stroke pathogenesis. These examples 
show that urine metabolomics has a diagnostic potential for several disorders that should be improved 
to overcome certain problems, such as the high biological variation in its composition, the 
standardization of urinary metabolomics procedures and the validations of previous reports. 
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3.1. MEPS and SPME Advantages for the Metabolic Profile of Urine 
In the previous section, a large number of selected applications showed the potentialities of the 
metabolic profile of urine in unveiling many diseases processes and pointing to new directions and 
their treatments. In most cases, however, instead of specific metabolites, we have information about 
up- or down-regulated pathways, but this information is too complex to be used in the clinical disease 
diagnostics. Furthermore, to make this information biochemically relevant, it would require long and 
complex analysis. Therefore, these metabolic profiles should instead provide biomarkers able to be 
readily used in disease biomarker. In this sense, SPME and MEPS are suitable for fulfilling this 
objective of breaking urine metabolomic complexity. Different high throughput solutions are 
nowadays available to easily process a large amount of samples, speeding up metabolomic research. 
Several applications in different fields of research have been reviewed [9,61,62], but here, we will 
focus in more detail on specific applications to the most prevalent human diseases, Cardiovascular 
(CVDs), oncologic (ODs) and neurodegenerative diseases (NDDs). 
3.2. Early Diagnosis of Highly Prevalent Diseases, Such As Cardiovascular, Oncologic and 
Neurodegenerative Ones 
CVDs, ODs and NDDs are the three main causes of mortality worldwide. Moreover, the morbidity 
burden associated with these diseases is also very high, presenting an increasing trend that is 
proportional to the rise in life expectancy. The main cause of this scenario is the late diagnosis of these 
diseases, which, moreover, is usually performed in invasive and expensive formats, when the diseases 
already have reached the medium to late stages. Therefore, there is a great potential to unveil using 
urine as a tool to achieve an early and potentially inexpensive disease diagnose. Although these 
diseases develop slowly and progress in a relative asymptomatic way till they reach an advanced stage 
development, there are certainly causes and modifications that can be assessed in order to obtain an 
early diagnosis, particularly specific metabolites, whose levels are necessarily different from the 
healthy status. Oxidative damage to the cell components (particularly lipids of the membrane layer, 
proteins and nucleic acids) caused by reactive oxygen and nitrogen species (ROS and RNS, 
respectively) is nowadays recognized as a hallmark in these diseases. In fact, several reports point to 
oxidative damage as a triggering event in different ODs, NDDs and CVDs [63–66]. CVD progression, 
for instance, is characterized by an increase in lipid peroxidation that causes vascular lesions, 
inflammation events and, finally, atherosclerosis [67,68]. Therefore, there should be different 
metabolites that reflect these events, these being potentially suitable biomarkers for the early diagnosis 
of CVD progression. The success of this approach depends, however, on powerful analytical methodologies 
able to reliably characterize metabolites in vestigial concentrations. In the last few years, improvements 
in liquid chromatography (LC), gas chromatography (GC) and mass spectrometry (MS) have allowed an 
unprecedented analytical performance, able to go deeper into the characterization on new disease 
biomarkers. If properly conjugated with microextraction techniques (METs), namely MEPS and SPME, 
the limit of the single molecule quantification is increasingly closer. This fulfills the metabolomic 
characterization of the main human diseases that is necessary to find the best biomarkers for an early 
diagnosis. Additionally, the powerful analytical performance that can be obtained by using high throughput 
Metabolites 2014, 4 83 
 
 
platforms conjugating METs with LC, GC and MS is being successfully used in the characterization of 
a vast number of drugs and drugs metabolites used against diseases (reviewed in [13,61,62]). This 
allows for a sophisticated therapeutic drug monitoring that is critical for the success of the treatment of 
many diseases, particularly CVDs, OD and NDDs [69]. Several relevant reports on this subject are 
described in Table 2. Additionally, some applications using SPE will be also highlighted, which would 
greatly benefit from an upgrade to the MEPS methodology. 
Table 2. Representative reports using MEPS and SPME methodologies in the characterization 
of target urinary metabolites.  
Target diseases or analytes 
LOD LOQ 
Analytical method Reference 
(ng·mL−1 by default) 
CVDs 
F2-Isoprostanes (oxidative  
damage biomarker) 
- - SPE/LC-MS [70–73] 
- - SPE/GC-MS [74,75] 
-KG, L-CAR and acetyl-L-CAR  
(cardiac cell metabolism) 
- 0.04–0.08 SPME/LC-MS [76] 
CVDs drugs 
Aliskiren, prasugrel and rivaroxaban - 0.5–5.0 pg·mL−1 MEPS/LC-MS/MS [77] 
Pravastatin and pravastatin lactone 1.5 nM 5 nM SPME/LC-MS [78] 
Stimulants and β-blockers 0.1–1.2 - SPME/LC-MS [79] 
Acebutolol and metoprolol - 1.0 MEPS/LC-MS/MS [80] 
Propranolol  4–7 13–20 SPME/CEC [81] 
Verapamil, propranolol and metoprolol - - MEPS/µPESI-MS/MS [82] 
Verapamil, gallopamil, norverapamil 52–63, 5–8 - SPME/LC-UV (LC-MS) [83] 
Lidocaine 1.0 5.0 MEPS/LC-MS/MS [36,84] 
ODs 
Hexanal and heptanal (lung cancer) 0.10–0.11 0.21–0.23 
SPME/GC-MS 
[85] 
Breast cancer VOCs - - [41] 
Prostate cancer VOCs 0.10 0.16 [86] 
Sarcosine and N-ethylglycine - 0.03–0.06 [87] 
Neuroendocrine tumor markers  
(HVA, VMA, 5-HIAA) 
0.046–24.3 0.063–49.6 SPME/GC-QqQ-MS [88] 
Unrelated cancer forms - - SPME/GC-MS [89] 
5-HMUra and 8-oxodG  
(oxidatively damaged DNA) 
0.05–4.0 0.23–130.0 MEPS/LC-PDA [90] 
8-hydroxy-2′-deoxyguanosine 
(oxidatively damaged DNA) 
2.04 nM 7.12 nM SPME/LC-UV [91] 
2.61 nM 8.63 nM SPME/CE-ECD [92] 
ODs 
17β-estradiol and 2-methoxyestradiol 
(potential angiogenesis modulators) 
- - SPME/GC–MS [93] 
Roscovitine (potential anticancer drug) 0.5 1.0 MEPS/LC-MS/MS [94] 
Olomoucine (potential anticancer drug) 0.5 1.0 MEPS/LC-MS/MS [95] 
Acrolein (lipid peroxidation by-product 
and metabolite of cyclophosphamide and  
ifosfamide (anticancer drugs)) 
- - SPME/GC–MS [96] 
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Table 2. Cont. 
Target diseases or analytes 
LOD LOQ 
Analytical method Reference 
(ng·mL−1 by default) 
NDDs 
Selegiline and desmethylselegiline (PD 
drugs) 
0.01–0.05 0.05–20 SPME/GC–MS [97] 
Catecholamines (elevated in several CVDs an NDDs) 
Serotonin, dopamine and noradrenaline 2–20 5–50 MEPS/LC-ECD [98] 
Dopamine and serotonin 1 50 MEPS/LC-MS/MS [99] 
Dopamine 1.2 4.0 SPME/LC-ESI-MS/MS [100] 
Dopamine, epinephrine and norepinephrine 4.8–7.4 (nM) - SPME/EC-UV [101] 
non-polar heterocyclic amines  
(high carcinogenic potential) 
1.6–5.6 5.5–18.7 MEPS/CLC-FLD [102] 
Abbreviations: 5-HMUra, 5-hydroxymethyluracil; 5-HIAA, 5-hydroxyindolacetic acid 8-oxodG,  
8-oxo-7,8-dihydro-2′-deoxyguanosine; AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CAR, 
carnitine; CEC, Capillary electrochromatography, CLC-FLD, capillary liquid chromatography - fluorometric 
detection; CVDs, cardiovascular diseases; GC-MS, gas chromatography-mass spectrometry, GC-QqQ-MS/MS, 
gas chromatography-triple quadrupole-mass spectrometry; HPLC-PDA, high performance liquid chromatography 
with photodiode array detection; HVA, homovanillic acid; KG, ketoglutaric acid, LC-ED, high performance 
liquid chromatography coupled to electrochemical detection; LC-ESI/MS, liquid chromatography coupled to 
an electrospray ionization mass spectrometer; LC-CD, liquid chromatography with colorimetric detection; 
LC-FLD, liquid chromatography with fluorescence detection; LC-MS/MS, liquid chromatography-tandem 
mass spectrometry; LC-UV, liquid chromatography coupled to an ultraviolet detector; LOD, limit of 
detection; LOQ, limit of quantification; METs, microextraction techniques; NDDs, neurodegenerative 
diseases; ODs, oncologic diseases; PD, Parkinson’s disease; SPME, solid-phase microextraction;  
µPESI-MS/MS, micropillar array electrospray ionization mass spectrometry; VMA, vanilmandelic acid; 
VOCs, volatile organic compounds. 
3.2.1. CVDs 
CVDs designate several heterogeneous circulation disorders that include rheumatic, hypertensive, 
ischemic, cerebrovascular and inflammatory heart diseases. These conditions are primarily caused by 
an early and asymptomatical atherosclerosis that progresses gradually through adolescence and early 
adulthood [103]. Their diagnose is still nowadays performed through the widely conventional risk 
factors associated with the onset of CVDs, such as high blood pressure, hypercholesterolemia, age, 
gender, obesity, life style abuses, etc. However, these parameters are not suitable for an early 
diagnostic of CVD progression, at least if not conjugated with other biochemical biomarkers. 
Moreover, they are also not able to predict sudden and fatal occurrences of CVDs, such as acute 
myocardial infarctions and strokes. In this way, there are interesting reports pointing to other directions, 
particularly to oxidative damage biomarkers. F2-isoprostanes and 8-OHdG are generally accepted as 
biomarkers for monitoring oxidative status over time [104], and in fact, there are several reports 
suggesting F2-isoprostanes as prognostic CVD biomarkers ([105] and the references within [106,107]). 
F2-isoprostanes, which are generated by the free radical-mediated peroxidation of arachidonic acid, a 
key component of the cell membrane, are mainly quantified by LC-MS or GC-MS following an SPE 
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extraction [70–75,104,108] or ELISA, although the reliability of this approach is strongly affected by 
antibody cross-reactivity issues [109]. The utilization of MEPS would certainly raise the analytical 
performance obtained in the methods described, allowing for a deeper understanding of the power of 
F2-isoprostanes as CVD biomarkers. Using this extraction procedure, Mendes et al. [110] reported 
another putative correlation between oxidative damage and CVDs. Although very preliminary, their 
results suggest a positive correlation between the urinary levels of the oxidatively damaged DNA 
adducts, 8-oxo-7,8-dihydro-29-deoxyguanosine (8-oxodG) and 5-hydroxymethyluracil (5-HMUra) and 
CVDs risk progression. Magiera et al. [76], in turn, focus their studies on α-ketoglutaric acid (KG),  
L-carnitine (CAR) and acetyl-L-CAR, which are molecules that have an important role in cardiac cell 
metabolism, this being very important for the outcome of a cardiac injury. In this case, the authors 
used a two-step SPE procedure using silica gel and quaternary amine cartridges for sample cleanup, 
which limits the high throughput potential of the methodology. A large number of drugs used for 
different CVD etiologies are available nowadays, raising questions about the possible side effects and 
drug interactions. As pointed out by Baranowska et al. [111], several studies show that the most 
common causes of adverse events in a hospitalized patients review are related to cardiovascular drug 
treatments. Therefore, the existence of reliable methodologies to follow the effects of these drugs and 
their metabolites in the organism is very pertinent. To this point, we should highlight among the 
several examples shown in Table 2 the first reports for the quantification of urinary and plasmatic  
β-blockers using automated in-tube SPME coupled with LC/ESI-MS [112] and with LC-UV [113]. 
These drugs are widely used for the treatment of several CVDs (hypertension, angina pectoris and 
cardioarrhythmias), but they are very toxic and their therapeutic ranges very narrow [112]. In another 
report, El-Beqqali et al. [80] combined MEPS and LC–MS/MS to determine urinary acebutolol and 
metoprolol, β-adrenoceptor-blocking drugs used as anti-hypertensive and anti-anginal agents. 
Furthermore, the application of the same methodology for the quantification of the very recent and 
promising cardiac drugs aliskiren, prasugrel and rivaroxaban, is very relevant [77]. 
3.2.2. Oncologic Diseases (ODs) 
ODs are complex diseases triggered by different conditions and circumstances, but inevitably start 
with a cell that lost its normal homeostasis and started proliferating without control. These abnormal 
cells possess dramatically affected metabolisms, particularly at the glycolysis level (the “Warburg 
effect”), which they use to produce the amino acids, nucleotides and lipids necessary for their 
proliferation [114]. ODs will therefore produce changes that can be measured, whether they are 
changes in the abundance of certain compounds or new metabolites. Regarding this, the application of 
SPME to identify VOCs is a popular approach and has been successfully applied mainly to the 
characterization of the exhaled breath of cancer patients, particularly lung and breast cancer (reviewed 
in Pereira et al. [13]), but also urine. This is supported by several experimental observations, 
particularly the olfactory detection of prostate cancer by dogs sniffing urine [115]. Further evidences 
were obtained using SPME-GC/MS to characterize the urinary VOCs signatures for different forms of 
cancer, including lung [85], breast [40], lymphoma, leukemia and colorectal cancer [89] and prostate [86]. 
In most of these cases, a relevant part of the VOCs signatures is caused by oxidative damage, as in the 
case of the aliphatic hydrocarbons, such as the aldehydes ethane and pentane, which are the main  
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by-products of lipid peroxidation and oxidative DNA damage. This observation is supported by 
epidemiological evidence that clearly points to oxidative damage as one of the major sources of 
carcinogenesis [116]. However, as highlighted by Kwak and Preti [117], although some urinary 
disease-associated VOCs have been used in clinics, more experimental work is necessary to 
consistently demonstrate the strength of some of those applications. Regarding this, Monteleone et al. [88] 
developed a fast SPME/GC-QqQ (triple quadrupole)-MS methodology to quantify three catecholamines 
metabolites (homovanillic acid (HMA), vanilmandelic acid (VMA) and 5-hydroxyindoleacetic acid  
(5-HIAA)). Catecholamines, particularly noradrenaline, adrenaline and dopamine, are important 
neurotransmitters in the sympathetic nervous system, exerting cardiovascular and metabolic effects 
through adrenergic receptors stimulation in a wide variety of cells [118]. Their quantification is used in 
the diagnosis and management of patients with neurocrine tumors, such as phaeochromocytoma, and 
therefore, the application of this methodology in the clinical environment will have a major impact on 
the early diagnosis, disease progression and, in many cases, drug concentration, enabling important 
therapeutic drug monitoring (TDM) [13]. Additional works reporting the quantification of these 
catecholamines using MEPS and SPME are presented in Table 2 [98–100]. In another direction, 
Mendes et al. [90] used a fast and simple MEPS/LC-UV methodology to analyze the presence of 
oxidatively damaged DNA molecules in urine and reported that 8-oxodG levels are significantly 
augmented in breast and lung patients, while 5-HMUra is clearly less abundant in the urine from lung 
cancer patients in comparison to breast cancer and control samples. In turn, Barocas et al. [119] 
reported that oxidative stress measured by urinary F2-isoprostane levels is associated with prostate 
cancer. This work, performed in an SPE/GC-MS format, shows the potential of F2-isoprostanes as 
biomarkers of prostate cancer. A microextraction approach applied to other ODs is therefore very 
pertinent and certainly will clarify if F2-isoprostane can be used as an OD biomarker. 
3.2.3. Neurodegenerative Diseases (NDDs) 
The accumulation of oxidative damage has been implicated in aging and various neurological 
disorders, including Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic lateral 
sclerosis (ALS) [120,121]. Therefore, the search for urinary biomarkers of NDDs was primarily 
focused on oxidative damage biomarkers. To this point, Bolner et al. [122] showed that 8-OHdG 
alone, as well as the ratio 8-OHdG/2-dG (the corresponding non-hydroxylated base, 2′-deoxyguanosine) 
were significantly different in healthy controls and Parkinson disease (PD) patients. Similarly, 
Bogdanov et al. [123] reported increased levels of free 8-OHdG in urine, plasma and cerebrospinal 
fluid (CSF) of ALS patients. These is, therefore, important evidence that support the importance of  
8-OHdG as a biomarker to complement NDDs diagnosis, and a faster methodology using 
MEPS/UHPLC-UV has been already described [90,110]. Regarding F2-isoprostanes as biomarkers of 
oxidative stress, unlike the CVDs ([105] and references within, [106,107]) and ODs [119], there are 
conflicting results about their role as biomarkers in different NDDs, such as AD, PD, ALS or 
Huntington’s diseases [124–130]. This inconsistency is probably due to the inability of some of the 
methodologies developed to differentiate between the several isoprostane isoforms, originating 
misleading results that need to be clarified with further studies. However, as there is a clear increase in 
the lipoperoxidation products, malondialdehyde (MDA) and 4-hydroxy-2-nonenal (4-HNE) in fibroblasts 
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and lymphoblasts of familial AD [131], it is very plausible that isoprostanes, at least some isoforms, 
also by-products of lipid peroxidation, are increased in most NDDs. As shown by Cecchi et al. [131], 
MDA quantification in urine is a promising opportunity to improve NDDs diagnosis, and a fast and 
reliable MEPS/UHPLC-UV methodology for the simultaneous quantification of MDA and 8-OHdG 
has been already described [90,110]. Finally, Davidson et al. [132] showed that PD patients under  
L-dopa treatment present significantly higher values for urinary dopamine, homovanillic acid, free 
normetadrenaline and free metadrenaline. L-dopa is a precursor of dopamine and other catecholamines 
and an important antiparkinsonian drug. Therefore, this is an interesting TDM application that could be 
improved by the utilization of fast MEPS or SPME strategies, such as the ones reported for dopamine 
quantification [98–100]. 
4. Concluding Remarks 
Urine is a biological matrix with a great potential for the early diagnosis of the highly prevalent 
CVDs, ODs and NDDs that has not yet been fully explored. 
The major reason for this potential is that human metabolism under disease conditions is necessarily 
different from the steady state, producing changes in the presence and abundance of specific metabolites. 
In this way, metabolomics is a growing and powerful technology capable of detecting hundreds to 
thousands of metabolites in tissues and biofluids (Figure 6). These metabolites, if properly identified, 
may contribute to a faster, reliable and non-invasive method of diagnosis. Urine has not been fully explored 
as an early diagnosis method, and its complexity (it contains, at least, 3,079 detectable metabolites, as 
Bouatra et al. [133] very recently reported in the human urine metabolome database) and the analytical 
difficulties in identifying and quantifying vestigial metabolites are certainly the two main reasons 
accounting for that fact. Microextraction techniques, such as SPME and MEPS, can be successfully 
used to simplify this complexity and improve the analytical performance of the LC, GC and MS available 
nowadays even more, allowing for the characterization of the metabolite profile, which can be reliably 
used for an early diagnosis of a given disease, namely the CVDs, ODs and NDDs analyzed here. 
Figure 6. Flowchart for the SPME and MEPS high throughput potential applied to urinalysis 
for the metabolic profiling of urine and the early diagnosis of high prevalent diseases. 
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One of the future aspects of SPME and MEPS for clinical bioanalysis by metabolomics profiling 
studies would be using in vivo SPME models, such as humans, rather than in rats or dogs, as they are 
performed at the moment (reviewed in [13]). This kind of application would be very interesting  
once the information obtained is more accurate and in the real-time functioning of the organism.  
This approach would reduce contact with biological fluids and contamination issues. Regarding 
MEPS, it would be interesting to study the potential of this extraction technique in metabolites from 
urine, as described in the previous section, as a promising fluid for the screening of diseases. 
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